TABLE 1.

Input parameters.

Parameters	Value	Range	Distribution	Source
Rate of Grade 3–4 AEs with RT plus TMZ	54.8%	43.84–65.76%	Beta	Perry et al. (2017)
Rate of Grade 3–4 AEs with RT alone	11.9%	9.52–14.28%	Beta	Perry et al. (2017)
Costs in China (¥)
RT per fractions	840	672–1,008	Gamma	Wu et al. (2012)
TMZ per 20 mg	200	160–240	Gamma	Local charge
AE management	2,700	2,160–3,240	Gamma	Wu et al. (2012)
PD state treatment	1,050	840–1,260	Gamma	Wu et al. (2012)
MRI	600	480–720	Gamma	Local charge
Blood test	200	160–240	Gamma	Local charge
Clinical visit	60	48–72	Gamma	Local charge
PFS supportive care	500	400–600	Gamma	Local charge
PD supportive care	2000	1,600–2,400	Gamma	Local charge
Costs in the US ($)
RT per fractions	1,618	1,295–1942	Gamma	Messali et al. (2013)
TMZ per 20 mg	25	20–30	Gamma	Messali et al. (2013)
AE management	10,430	8,344–12,516	Gamma	Guzauskas et al. (2019)
PD state treatment	2,992	2,394–3,591	Gamma	Qian et al. (2017)
MRI	850	680–1,020	Gamma	Qian et al. (2017)
Blood test	335	268–402	Gamma	Qian et al. (2017)
Clinical visit	734	587–881	Gamma	Messali et al. (2013)
PFS supportive care	138	110–165	Gamma	Guzauskas et al. (2019)
PD supportive care	1,126	901–1,352	Gamma	Guzauskas et al. (2019)
Utilities
PFS	0.887	0.7096–1	Beta	Garside et al. (2007)
PFS with RT	0.824	0.6592–0.9888	Beta	Garside et al. (2007)
PFS with TMZ	0.733	0.5864–0.8796	Beta	Garside et al. (2007)
PFS with RT plus TMZ	0.743	0.5944–0.8916	Beta	Garside et al. (2007)
PD	0.731	0.5848–0.8772	Beta	Garside et al. (2007)

AE: adverse event; MRI: magnetic resonance imaging; PD: progressive disease; PFS: progression-free survival; RT: radiotherapy; TMZ: temozolomide